EGFR and non-small cell lung carcinoma: To do this, we had access to the AURA2 [NCT02094261] [8] and AURA3 [NCT02151981] [9] clinical studies, which collected both QLQ-C30 and EQ-5D-5 L questionnaires in previously treated EGFR and T790M mutation-positive NSCLC patients.